uuid	gene_curie	gene_symbol	disease_curie	disease_title	disease_original_curie	disease_original_title	classification_curie	classification_title	moi_curie	moi_title	submitter_curie	submitter_title	submitted_as_hgnc_id	submitted_as_hgnc_symbol	submitted_as_disease_id	submitted_as_disease_name	submitted_as_moi_id	submitted_as_moi_name	submitted_as_submitter_id	submitted_as_submitter_name	submitted_as_classification_id	submitted_as_classification_name	submitted_as_date	submitted_as_public_report_url	submitted_as_notes	submitted_as_pmids	submitted_as_assertion_criteria_url	submitted_as_submission_id	submitted_run_date
GENCC_000101-HGNC_10896-OMIM_182212-HP_0000006-GENCC_100001	HGNC:10896	SKI	MONDO:0008426	Shprintzen-Goldberg syndrome	OMIM:182212	OMIM:182212	GENCC:100001	Definitive	HP:0000006	Autosomal dominant	GENCC:000101	Ambry Genetics	HGNC:10896	SKI	OMIM:182212	Shprintzen-Goldberg syndrome	HP:0000006	Autosomal dominant inheritance	GENCC:000101	Ambry Genetics	GENCC:100001	Definitive	2018-03-30 13:31:56				PMID: 28106320	1034	2020-12-24
GENCC_000101-HGNC_16636-OMIM_171300-HP_0000006-GENCC_100003	HGNC:16636	KIF1B	MONDO:0008233	phaeochromocytoma	OMIM:171300	OMIM:171300	GENCC:100003	Moderate	HP:0000006	Autosomal dominant	GENCC:000101	Ambry Genetics	HGNC:16636	KIF1B	OMIM:171300	Pheochromocytoma	HP:0000006	Autosomal dominant inheritance	GENCC:000101	Ambry Genetics	GENCC:100003	Moderate	2019-12-04 13:30:43				PMID: 28106320	69237	2020-12-24
GENCC_000101-HGNC_16636-OMIM_118210-HP_0000006-GENCC_100003	HGNC:16636	KIF1B	MONDO:0007308	Charcot-Marie-Tooth disease type 2A1	OMIM:118210	OMIM:118210	GENCC:100003	Moderate	HP:0000006	Autosomal dominant	GENCC:000101	Ambry Genetics	HGNC:16636	KIF1B	OMIM:118210	Charcot-Marie-Tooth disease, type 2A1	HP:0000006	Autosomal dominant inheritance	GENCC:000101	Ambry Genetics	GENCC:100003	Moderate	2020-10-29 13:30:43				PMID: 28106320	69237	2020-12-24
GENCC_000101-HGNC_17939-OMIM_617532-HP_0000007-GENCC_100004	HGNC:17939	SLC45A1	MONDO:0044322	intellectual developmental disorder with neuropsychiatric features	OMIM:617532	OMIM:617532	GENCC:100004	Limited	HP:0000007	Autosomal recessive	GENCC:000101	Ambry Genetics	HGNC:17939	SLC45A1	OMIM:617532	Intellectual developmental disorder with neuropsychiatric features	HP:0000007	Autosomal recessive inheritance	GENCC:000101	Ambry Genetics	GENCC:100004	Limited	2020-06-26 13:32:00				PMID: 28106320	72178	2020-12-24
GENCC_000101-HGNC_11071-OMIM_616291-HP_0000007-GENCC_100004	HGNC:11071	SLC9A1	MONDO:0014572	Lichtenstein-Knorr syndrome	OMIM:616291	OMIM:616291	GENCC:100004	Limited	HP:0000007	Autosomal recessive	GENCC:000101	Ambry Genetics	HGNC:11071	SLC9A1	OMIM:616291	Lichtenstein-Knorr syndrome	HP:0000007	Autosomal recessive inheritance	GENCC:000101	Ambry Genetics	GENCC:100004	Limited	2018-08-31 13:32:02				PMID: 28106320	1705	2020-12-24
GENCC_000101-HGNC_406-OMIM_239510-HP_0000007-GENCC_100004	HGNC:406	ALDH4A1	MONDO:0009401	hyperprolinemia type 2	OMIM:239510	OMIM:239510	GENCC:100004	Limited	HP:0000007	Autosomal recessive	GENCC:000101	Ambry Genetics	HGNC:406	ALDH4A1	OMIM:239510	Hyperprolinemia, type II	HP:0000007	Autosomal recessive inheritance	GENCC:000101	Ambry Genetics	GENCC:100004	Limited	2020-06-19 13:29:20				PMID: 28106320	5173	2020-12-24
GENCC_000101-HGNC_18806-OMIM_614756-HP_0000006-GENCC_100002	HGNC:18806	CAMTA1	MONDO:0013886	nonprogressive cerebellar atxia with mental retardation	OMIM:614756	OMIM:614756	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000101	Ambry Genetics	HGNC:18806	CAMTA1	OMIM:614756	Cerebellar ataxia, nonprogressive, with mental retardation	HP:0000006	Autosomal dominant inheritance	GENCC:000101	Ambry Genetics	GENCC:100002	Strong	2020-11-06 13:29:37				PMID: 28106320	69618	2020-12-24
GENCC_000101-HGNC_16369-OMIM_606324-HP_0000007-GENCC_100003	HGNC:16369	PARK7	MONDO:0011658	autosomal recessive early-onset Parkinson disease 7	OMIM:606324	OMIM:606324	GENCC:100003	Moderate	HP:0000007	Autosomal recessive	GENCC:000101	Ambry Genetics	HGNC:16369	PARK7	OMIM:606324	Parkinson disease 7, autosomal recessive early-onset	HP:0000007	Autosomal recessive inheritance	GENCC:000101	Ambry Genetics	GENCC:100003	Moderate	2018-08-31 13:31:17				PMID: 28106320	88987	2020-12-24
GENCC_000101-HGNC_4286-OMIM_617524-HP_0000007-GENCC_100004	HGNC:4286	GJB4	MONDO:0033012	erythrokeratodermia variabilis et progressiva 2	OMIM:617524	OMIM:617524	GENCC:100004	Limited	HP:0000007	Autosomal recessive	GENCC:000101	Ambry Genetics	HGNC:4286	GJB4	OMIM:617524	Erythrokeratodermia variabilis et progressiva 2	HP:0000007	Autosomal recessive inheritance	GENCC:000101	Ambry Genetics	GENCC:100004	Limited	2020-10-15 13:30:22				PMID: 28106320	864790	2020-12-24
GENCC_000101-HGNC_10866-OMIM_615006-HP_0000007-GENCC_100004	HGNC:10866	ST3GAL3	MONDO:0014003	developmental and epileptic encephalopathy, 15	OMIM:615006	OMIM:615006	GENCC:100004	Limited	HP:0000007	Autosomal recessive	GENCC:000101	Ambry Genetics	HGNC:10866	ST3GAL3	OMIM:615006	Developmental and epileptic encephalopathy 15	HP:0000007	Autosomal recessive inheritance	GENCC:000101	Ambry Genetics	GENCC:100004	Limited	2020-06-28 13:32:07				PMID: 28106320	1054	2020-12-24
GENCC_000101-HGNC_30563-OMIM_618437-HP_0000007-GENCC_100003	HGNC:30563	PARS2	MONDO:0032752	developmental and epileptic encephalopathy, 75	OMIM:618437	OMIM:618437	GENCC:100003	Moderate	HP:0000007	Autosomal recessive	GENCC:000101	Ambry Genetics	HGNC:30563	PARS2	OMIM:618437	Epileptic encephalopathy, early infantile, 75	HP:0000007	Autosomal recessive inheritance	GENCC:000101	Ambry Genetics	GENCC:100003	Moderate	2020-06-18 13:31:17				PMID: 28106320	67349	2020-12-24
GENCC_000101-HGNC_15469-OMIM_615528-HP_0000007-GENCC_100003	HGNC:15469	DNAJC6	MONDO:0014231	juvenile onset Parkinson disease 19A	OMIM:615528	OMIM:615528	GENCC:100003	Moderate	HP:0000007	Autosomal recessive	GENCC:000101	Ambry Genetics	HGNC:15469	DNAJC6	OMIM:615528	Parkinson disease 19a, juvenile-onset	HP:0000007	Autosomal recessive inheritance	GENCC:000101	Ambry Genetics	GENCC:100003	Moderate	2018-08-31 13:29:58				PMID: 28106320	3563	2020-12-24
GENCC_000104-HGNC_23336-MONDO_0018997-HP_0000006-GENCC_100004	HGNC:23336	A2ML1	MONDO:0018997	Noonan syndrome	MONDO:0018997	Noonan syndrome	GENCC:100004	Limited	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:23336	A2ML1	MONDO:0018997	Noonan syndrome	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100004	Limited	2020-10-07 20:04:14	https://panelapp.genomicsengland.co.uk/panels/48/		24939586, 25862627, 27942422		000104.pa48.v1.73.hgnc23336.m1.p1	2020-10-08
GENCC_000104-HGNC_1097-OMIM_613707-HP_0000006-GENCC_100002	HGNC:1097	BRAF	MONDO:0013380	LEOPARD syndrome 3	OMIM:613707	OMIM:613707	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:1097	BRAF	OMIM:613707	LEOPARD syndrome 3 613707	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:14	https://panelapp.genomicsengland.co.uk/panels/48/		19206169, 21396583		000104.pa48.v1.73.hgnc1097.m1.p1	2020-10-08
GENCC_000104-HGNC_1097-OMIM_115150-HP_0000006-GENCC_100002	HGNC:1097	BRAF	MONDO:0007265	cardiofaciocutaneous syndrome 1	OMIM:115150	OMIM:115150	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:1097	BRAF	OMIM:115150	Cardiofaciocutaneous syndrome 115150	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:14	https://panelapp.genomicsengland.co.uk/panels/48/		19206169, 21396583		000104.pa48.v1.73.hgnc1097.m1.p2	2020-10-08
GENCC_000104-HGNC_1097-OMIM_613706-HP_0000006-GENCC_100002	HGNC:1097	BRAF	MONDO:0013379	Noonan syndrome 7	OMIM:613706	OMIM:613706	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:1097	BRAF	OMIM:613706	Noonan syndrome 7 613706	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:14	https://panelapp.genomicsengland.co.uk/panels/48/		19206169, 21396583		000104.pa48.v1.73.hgnc1097.m1.p3	2020-10-08
GENCC_000104-HGNC_1541-OMIM_613563-HP_0000006-GENCC_100002	HGNC:1541	CBL	MONDO:0013308	CBL-related disorder	OMIM:613563	OMIM:613563	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:1541	CBL	OMIM:613563	Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia 613563	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:14	https://panelapp.genomicsengland.co.uk/panels/48/		20619386, 20543203, 19571318		000104.pa48.v1.73.hgnc1541.m1.p1	2020-10-08
GENCC_000104-HGNC_5173-OMIM_218040-HP_0000006-GENCC_100002	HGNC:5173	HRAS	MONDO:0009026	Costello syndrome	OMIM:218040	OMIM:218040	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:5173	HRAS	OMIM:218040	Costello syndrome	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:14	https://panelapp.genomicsengland.co.uk/panels/48/		16170316, 16969868, 16443854, 21396583		000104.pa48.v1.73.hgnc5173.m1.p1	2020-10-08
GENCC_000104-HGNC_6407-OMIM_609942-HP_0000006-GENCC_100002	HGNC:6407	KRAS	MONDO:0012371	Noonan syndrome 3	OMIM:609942	OMIM:609942	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:6407	KRAS	OMIM:609942	Noonan syndrome 3 609942	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:14	https://panelapp.genomicsengland.co.uk/panels/48/		21396583		000104.pa48.v1.73.hgnc6407.m1.p1	2020-10-08
GENCC_000104-HGNC_6407-OMIM_615278-HP_0000006-GENCC_100002	HGNC:6407	KRAS	MONDO:0014112	cardiofaciocutaneous syndrome 2	OMIM:615278	OMIM:615278	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:6407	KRAS	OMIM:615278	Cardiofaciocutaneous syndrome 2 615278	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		21396583		000104.pa48.v1.73.hgnc6407.m1.p2	2020-10-08
GENCC_000104-HGNC_6742-OMIM_616564-HP_0000006-GENCC_100002	HGNC:6742	LZTR1	MONDO:0014693	Noonan syndrome 10	OMIM:616564	OMIM:616564	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:6742	LZTR1	OMIM:616564	Noonan syndrome 10 616564	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		25795793, 29469822		000104.pa48.v1.73.hgnc6742.m1.p1	2020-10-08
GENCC_000104-HGNC_6742-OMIM_615670-HP_0000006-GENCC_100002	HGNC:6742	LZTR1	MONDO:0014299	schwannomatosis 2	OMIM:615670	OMIM:615670	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:6742	LZTR1	OMIM:615670	Schwannomatosis-2, susceptibility to 615670	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		25795793, 29469822		000104.pa48.v1.73.hgnc6742.m1.p2	2020-10-08
GENCC_000104-HGNC_6742-OMIM_605275-HP_0000007-GENCC_100002	HGNC:6742	LZTR1	MONDO:0011531	Noonan syndrome 2	OMIM:605275	OMIM:605275	GENCC:100002	Strong	HP:0000007	Autosomal recessive	GENCC:000104	Genomics England PanelApp	HGNC:6742	LZTR1	OMIM:605275	Noonan syndrome 2, 605275	HP:0000007	Autosomal recessive inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		25795793, 29469822		000104.pa48.v1.73.hgnc6742.m2.p3	2020-10-08
GENCC_000104-HGNC_6840-OMIM_615279-HP_0000006-GENCC_100002	HGNC:6840	MAP2K1	MONDO:0014113	cardiofaciocutaneous syndrome 3	OMIM:615279	OMIM:615279	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:6840	MAP2K1	OMIM:615279	Cardiofaciocutaneous syndrome 3	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		21396583, 23321623		000104.pa48.v1.73.hgnc6840.m1.p1	2020-10-08
GENCC_000104-HGNC_6840-MONDO_0007893-HP_0000006-GENCC_100002	HGNC:6840	MAP2K1	MONDO:0007893	Noonan syndrome with multiple lentigines	MONDO:0007893	Noonan syndrome with multiple lentigines	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:6840	MAP2K1	MONDO:0007893	Noonan syndrome with multiple lentigines	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		21396583, 23321623		000104.pa48.v1.73.hgnc6840.m1.p2	2020-10-08
GENCC_000104-HGNC_6842-OMIM_615280-HP_0000006-GENCC_100002	HGNC:6842	MAP2K2	MONDO:0014114	cardiofaciocutaneous syndrome 4	OMIM:615280	OMIM:615280	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:6842	MAP2K2	OMIM:615280	Cardiofaciocutaneous syndrome 4 615280	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		21396583, 23379592		000104.pa48.v1.73.hgnc6842.m1.p1	2020-10-08
GENCC_000104-HGNC_7227-OMIM_618499-HP_0000006-GENCC_100002	HGNC:7227	MRAS	MONDO:0032786	Noonan syndrome 11	OMIM:618499	OMIM:618499	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:7227	MRAS	OMIM:618499	Noonan syndrome 11, 618499	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		28289718, 31173466, 31108500, 31173466 		000104.pa48.v1.73.hgnc7227.m1.p1	2020-10-08
GENCC_000104-HGNC_7765-OMIM_601321-HP_0000006-GENCC_100002	HGNC:7765	NF1	MONDO:0011035	neurofibromatosis-Noonan syndrome	OMIM:601321	OMIM:601321	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:7765	NF1	OMIM:601321	Neurofibromatosis-Noonan syndrome 601321	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		16380919, 19845691, 12707950		000104.pa48.v1.73.hgnc7765.m1.p1	2020-10-08
GENCC_000104-HGNC_7765-OMIM_162200-HP_0000006-GENCC_100002	HGNC:7765	NF1	MONDO:0018975	neurofibromatosis type 1	OMIM:162200	OMIM:162200	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:7765	NF1	OMIM:162200	NEUROFIBROMATOSIS, TYPE 1 162200	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2021-02-11 13:01:31	https://panelapp.genomicsengland.co.uk/panels/734				000104.pa734.v1.11.hgnc:7765.m1.p1	2021-03-31
GENCC_000104-HGNC_7989-OMIM_613224-HP_0000006-GENCC_100002	HGNC:7989	NRAS	MONDO:0013186	Noonan syndrome 6	OMIM:613224	OMIM:613224	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:7989	NRAS	OMIM:613224	Noonan syndrome 6 613224	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		19966803, 19775298		000104.pa48.v1.73.hgnc7989.m1.p1	2020-10-08
GENCC_000104-HGNC_7989-MONDO_0015280-HP_0000006-GENCC_100002	HGNC:7989	NRAS	MONDO:0015280	cardiofaciocutaneous syndrome	MONDO:0015280	cardiofaciocutaneous syndrome	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:7989	NRAS	MONDO:0015280	Cardio-Facio-cutanenous syndrome	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		19966803, 19775298		000104.pa48.v1.73.hgnc7989.m1.p2	2020-10-08
GENCC_000104-HGNC_9282-OMIM_617506-HP_0000006-GENCC_100002	HGNC:9282	PPP1CB	MONDO:0054588	Noonan syndrome-like disorder with loose anagen hair 2	OMIM:617506	OMIM:617506	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:9282	PPP1CB	OMIM:617506	Noonan syndrome-like disorder with loose anagen hair 2, 617506	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:15	https://panelapp.genomicsengland.co.uk/panels/48/		27264673, 28211982, 27681385		000104.pa48.v1.73.hgnc9282.m1.p1	2020-10-08
GENCC_000104-HGNC_9644-OMIM_151100-HP_0000006-GENCC_100002	HGNC:9644	PTPN11	MONDO:0100082	LEOPARD syndrome 1	OMIM:151100	OMIM:151100	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:9644	PTPN11	OMIM:151100	LEOPARD syndrome 1 151100	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		17603483, 11704759, 12529711, 12634870, 15384080, 15240615, 16263833, 17497712, 18678287		000104.pa48.v1.73.hgnc9644.m1.p1	2020-10-08
GENCC_000104-HGNC_9644-OMIM_163950-HP_0000006-GENCC_100002	HGNC:9644	PTPN11	MONDO:0008104	Noonan syndrome 1	OMIM:163950	OMIM:163950	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:9644	PTPN11	OMIM:163950	Noonan syndrome 1 163950	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		17603483, 11704759, 12529711, 12634870, 15384080, 15240615, 16263833, 17497712, 18678287		000104.pa48.v1.73.hgnc9644.m1.p2	2020-10-08
GENCC_000104-HGNC_9829-OMIM_611554-HP_0000006-GENCC_100002	HGNC:9829	RAF1	MONDO:0012691	LEOPARD syndrome 2	OMIM:611554	OMIM:611554	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:9829	RAF1	OMIM:611554	LEOPARD syndrome 2 611554	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		17603483, 17603482		000104.pa48.v1.73.hgnc9829.m1.p1	2020-10-08
GENCC_000104-HGNC_9829-OMIM_611553-HP_0000006-GENCC_100002	HGNC:9829	RAF1	MONDO:0012690	Noonan syndrome 5	OMIM:611553	OMIM:611553	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:9829	RAF1	OMIM:611553	Noonan syndrome 5 611553	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		17603483, 17603482		000104.pa48.v1.73.hgnc9829.m1.p2	2020-10-08
GENCC_000104-HGNC_10023-OMIM_615355-HP_0000006-GENCC_100002	HGNC:10023	RIT1	MONDO:0014143	Noonan syndrome 8	OMIM:615355	OMIM:615355	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:10023	RIT1	OMIM:615355	Noonan syndrome 8 615355	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		23791108, 25124994, 24939608		000104.pa48.v1.73.hgnc10023.m1.p1	2020-10-08
GENCC_000104-HGNC_10447-MONDO_0018997-HP_0000006-GENCC_100003	HGNC:10447	RRAS	MONDO:0018997	Noonan syndrome	MONDO:0018997	Noonan syndrome	GENCC:100003	Moderate	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:10447	RRAS	MONDO:0018997	Noonan syndrome	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100003	Moderate	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		24705357		000104.pa48.v1.73.hgnc10447.m1.p1	2020-10-08
GENCC_000104-HGNC_17271-OMIM_618624-HP_0000006-GENCC_100002	HGNC:17271	RRAS2	MONDO:0032839	noonan syndrome 12	OMIM:618624	OMIM:618624	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:17271	RRAS2	OMIM:618624	Noonan syndrome 12, 618624	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		31130282, 31130285		000104.pa48.v1.73.hgnc17271.m1.p1	2020-10-08
GENCC_000104-HGNC_15454-OMIM_607721-HP_0000006-GENCC_100002	HGNC:15454	SHOC2	MONDO:0054637	Noonan syndrome-like disorder with loose anagen hair 1	OMIM:607721	OMIM:607721	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:15454	SHOC2	OMIM:607721	Noonan syndrome-like with loose anagen hair 1, 607721	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		19684605, 22528146, 23918763		000104.pa48.v1.73.hgnc15454.m1.p1	2020-10-08
GENCC_000104-HGNC_11187-OMIM_610733-HP_0000006-GENCC_100002	HGNC:11187	SOS1	MONDO:0012547	Noonan syndrome 4	OMIM:610733	OMIM:610733	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:11187	SOS1	OMIM:610733	Noonan syndrome 4 610733	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		19438935, 17143285, 17143282, 17586837		000104.pa48.v1.73.hgnc11187.m1.p1	2020-10-08
GENCC_000104-HGNC_11188-OMIM_616559-HP_0000006-GENCC_100002	HGNC:11188	SOS2	MONDO:0014691	Noonan syndrome 9	OMIM:616559	OMIM:616559	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:11188	SOS2	OMIM:616559	Noonan syndrome 9 616559	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		25795793, 26173643		000104.pa48.v1.73.hgnc11188.m1.p1	2020-10-08
GENCC_000104-HGNC_20249-OMIM_611431-HP_0000006-GENCC_100002	HGNC:20249	SPRED1	MONDO:0012669	Legius syndrome	OMIM:611431	OMIM:611431	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000104	Genomics England PanelApp	HGNC:20249	SPRED1	OMIM:611431	Legius syndrome 611431	HP:0000006	Autosomal dominant inheritance	GENCC:000104	Genomics England PanelApp	GENCC:100002	Strong	2020-10-07 20:04:16	https://panelapp.genomicsengland.co.uk/panels/48/		17704776, 19366998, 19443465, 21649642, 21548021		000104.pa48.v1.73.hgnc20249.m1.p1	2020-10-08
GENCC_000105-HGNC_31042-MONDO_0024520-HP_0000006-GENCC_100001	HGNC:31042	GREB1L	MONDO:0024520	renal hypodysplasia/aplasia 3	MONDO:0024520	renal hypodysplasia/aplasia 3	GENCC:100001	Definitive	HP:0000006	Autosomal dominant	GENCC:000105	Illumina	HGNC:31042	GREB1L	MONDO:0024520	renal hypodysplasia/aplasia 3	HP:0000006	Autosomal dominant inheritance	GENCC:000105	Illumina	GENCC:100001	Definitive	2020-09-30 00:00:00		The GREB1L gene is located on chromosome 18 at q11.1-11.2 and encodes the GREB1 like retinoic acid receptor coactivator protein, which is involved with retinoic acid signaling and is essential for early metanephros and genital development. GREB1L was first reported in relation to autosomal dominant renal agenesis and hypodysplasia (RHD) in 2017 (28739660; Brophy et al. 2017).  At least seven unique variants including missense and loss-of-function variants have been reported in the literature. Evidence supporting this gene-disease relationship includes case-level data, segregation data, and experimental data. Variants in this gene have been reported in at least nine probands from three publications (28739660; Brophy et al. 2017; 29100091; Tomasi et al. 2017; 29100090; Sanna-Cherchi et al. 2017). Although segregation was observed in six families, incomplete penetrance was also noted. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. This gene-disease relationship is supported by animal models and expression studies (Tomasi et al. 2017). In summary, GREB1L is definitively associated with autosomal dominant renal agenesis and hypodysplasia (RHD).	28739660, 29100090, 29100091, 31424080	https://www.clinicalgenome.org/site/assets/files/3975/gene-disease_validity_standard_operating_procedures_version_7-1.pdf	100001	2020-10-15
GENCC_000105-HGNC_11916-MONDO_0007727-HP_0000006-GENCC_100001	HGNC:11916	TNFRSF1A	MONDO:0007727	autosomal dominant familial periodic fever	MONDO:0007727	autosomal dominant familial periodic fever	GENCC:100001	Definitive	HP:0000006	Autosomal dominant	GENCC:000105	Illumina	HGNC:11916	TNFRSF1A	MONDO:0007727	familial periodic fever	HP:0000006	Autosomal dominant inheritance	GENCC:000105	Illumina	GENCC:100001	Definitive	2020-10-01 00:00:00		The TNFRSF1A gene is located on chromosome 12 at 12p13.31 and encodes the TNF receptor superfamily member 1A protein, which is one of two membrane receptors bound by the proinflammatory cytokine TNF. TNFRSF1A was first reported in relation to familial periodic fever in 1999 (10199409: McDermott et al. 1999). Evidence supporting this gene-disease relationship includes case-level data and experimental data. At least 19 unique missense variants have been reported in 20 cases from eight publications (10199409: McDermott et al. 1999; 10902757: Dode et al. 2000; 13130484: Aganna et al. 2003; 16508982: D'Osualdo et al. 2006; 22566169: Jesus et al. 2012; 23322460: Havla et al. 2013; 22343913: Lee et al. 2013; 25888769: Greco et al. 2015). More evidence is available in the literature, but the maximum score for probands with other variant type with some evidence of gene impact (7 pts) has been reached. This gene-disease relationship is supported by the biochemical function of TNFR1 signaling via two opposing pathways that lead to either apoptosis via caspase activation or to cellular survival and inflammation via the activation of NF-κB, functional alteration in patient and non-patient cells demonstrating reduced soluble TNFR1 impaired binding and intracellular signaling downstream of TNFR1, resulting in enhanced production of cytokines and chemokines (17666110: Kimberley et al. 2007; 16684962: Lobito et al. 2006; 20457915: Simon et al. 2010).  In two different knock-in mouse lines with TRAPS-associated variants in TNFRSF1A, TNFR1 accumulated intracellularly and there was enhanced activation of proinflammatory signaling. Heterozygous mice were hypersensitive to lipopolysaccharide (LPS), an endotoxin, which was also observed in TRAPS patient cells (20457915: Simon et al. 2010). In summary, TNFRSF1A is definitively associated with familial periodic fever. This has been repeatedly demonstrated in both research and clinical diagnostic settings, and has been upheld over time.	10199409, 10902757, 13130484, 16508982, 22566169, 23322460, 22343913, 25888769, 17666110, 20457915, 16684962	https://www.clinicalgenome.org/site/assets/files/3975/gene-disease_validity_standard_operating_procedures_version_7-1.pdf	100002	2020-10-15
GENCC_000105-HGNC_1463-MONDO_0032795-HP_0000006-GENCC_100004	HGNC:1463	CAMK2G	MONDO:0032795	intellectual developmental disorder 59	MONDO:0032795	intellectual developmental disorder 59	GENCC:100004	Limited	HP:0000006	Autosomal dominant	GENCC:000105	Illumina	HGNC:1463	CAMK2G	MONDO:0032795	CAMK2G-related syndromic intellectual disability	HP:0000006	Autosomal dominant inheritance	GENCC:000105	Illumina	GENCC:100004	Limited	2019-01-28 00:00:00			23033978, 30184290	https://clinicalgenome.org/site/assets/files/2165/gene_curation_sop_version_6_aug_2018_final.pdf	100003	2020-10-15
GENCC_000105-HGNC_15456-MONDO_0032721-HP_0000007-GENCC_100003	HGNC:15456	MBTPS1	MONDO:0032721	spondyloepiphyseal dysplasia, kondo-fu type	MONDO:0032721	spondyloepiphyseal dysplasia, kondo-fu type	GENCC:100003	Moderate	HP:0000007	Autosomal recessive	GENCC:000105	Illumina	HGNC:15456	MBTPS1	MONDO:0032721	spondyloepiphyseal dysplasia, kondo-fu type	HP:0000007	Autosomal recessive inheritance	GENCC:000105	Illumina	GENCC:100003	Moderate	2020-09-25 00:00:00		The MBTPS1 gene is located on chromosome 16 at 16q23.3-q24.1 and encodes membrane bound transcription factor peptidase, site 1. The site-1 protease, which is also referred to as S1P, is ubiquitously expressed in the Golgi and functions in cholesterol homeostasis, collagen trafficking, SREBP activation, lysosome biogenesis, and lysosomal enzyme trafficking. MBTPS1 was first reported in relation to autosomal recessive spondyloepiphyseal dysplasia, kondo-fu type in 2018 (30046013: Kondo et al. 2018). To date, two unique variants, a missense and a stop-gained, have been reported in two probands from two publications (30046013: Kondo et al. 2018; 32857899: Meyer et al. 2020). Clinical features reported in common in these individuals included poor growth, inguinal hernia, protruding ears, kyphosis, skeletal abnormalities involving the chest, and elevated plasma levels of lysosomal enzymes. Additional features observed in at least one of the cases included spondyloepiphyseal dysplasia, scoliosis, skeletal abnormalities involving the feet, motor delay, reduced bone density, failure to thrive with gastronomy tube, cataract, relative macrocephaly, triangular face, and prominent forehead and cheekbones.Evidence supporting this gene-disease relationship includes case-level data and experimental data. Loss of function (LOF) has been implicated as the mechanism of disease. This gene-disease relationship is also supported by strong expression in chondrocytes and skeletal tissue; the gene's functions in cholesterol homeostasis, collagen trafficking, SREBP activation, lysosome biogenesis, and lysosomal enzyme trafficking which are shared with other genes associated with overlapping phenotypes (e.g., MBTPS2, SREBP1, GNPTAB); a compound heterozygous zebrafish LOF mutant that shows skeletal, cartilage, collagen, and lipid abnormalities; morpholino-mediated knockdown in zebrafish that recapitulates the skeletal, chondrocyte, and cartilage abnormalities observed in the mutant; mice with chondrocyte-specific KO show skeletal abnormalities, chondrodysplasia, and signs of collagen abnormalities and ER stress; and patient fibroblasts and chondrocytes from patient iPSC-derived teratomas show defects in collagen trafficking and the unfolded protein response pathway in addition to increases in ER stress, lysosomes, and apoptosis (Schlombs et al. 2003; Patra et al. 2007; Kondo et al. 2018). In summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. Of note, heterozygous gain of function in this gene has also been implicated in a distinct phenotype in a single case (31070020: Schweitzer et al. 2019); this relationship will be assessed separately. 	30046013, 32420688, 18025304, 14612568	https://www.clinicalgenome.org/site/assets/files/3975/gene-disease_validity_standard_operating_procedures_version_7-1.pdf	100004	2020-10-15
GENCC_000105-HGNC_7785-MONDO_0032658-HP_0000006-GENCC_100002	HGNC:7785	NFIB	MONDO:0032658	macrocephaly, acquired, with impaired intellectual development	MONDO:0032658	macrocephaly, acquired, with impaired intellectual development	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000105	Illumina	HGNC:7785	NFIB	MONDO:0032658	acquired macrocephaly with impaired intellectual development	HP:0000006	Autosomal dominant inheritance	GENCC:000105	Illumina	GENCC:100002	Strong	2020-09-25 00:00:00		The NFIB gene is located on chromosome 9 at 9p23-p22.3 and encodes nuclear factor 1 B, a transcription factor that regulates adenovirus DNA replication and transcription throughout mammalian development. It has been specifically implicated in brain and lung development. NFIB was first reported in association with autosomal dominant acquired macrocephaly with impaired intellectual development in 2018 (30388402: Schanze et al. 2018). In addition to the primary features of intellectual disability and macrocephaly, additional features include motor and speech delay, behavioral abnormalities, corpus callosum abnormalities, seizures, hypotonia, genital anomalies, and other brain malformations. Variants in this gene have been reported in at least eight indviduals from two publications, including four predicted null and four missense variants (30388402: Schanze et al. 2018; 30315573: Kahrizi et al. 2019). Six of the variants occurred de novo, while one was identified in an affected parent-child pair. The maximum score for genetic evidence (12 pts.) has been reached. The mechanism for disease is haploinsufficiency. This gene-disease relationship is also supported by high expression in developing the brain, particularly in the cortical plate; a shared function as a transcriptional regulator that is shared with members of the same protein family that result in similar, overlapping phenotypes (e.g., NFIX, NFIA); and partial recapitulation of the human phenotype, including macrocephaly and callosal and other brain defects, in conventional and telencephalon-specific knockout mice (15632069: Steele-Perkins et al. 2005; 26021864: Bunt et al. 2015; 30388402: Schanze et al. 2018). In addition, in vitro analyses of patient-identified missense variants demonstrated disrupted transcriptional regulation in a luciferase assay (Schanze et al. 2018). In summary, there is strong evidence to support the relationship between NFIB and acquired macrocephaly with impaired intellectual development, autosomal dominant. Additional reports in humans published three years since the first proposal of the association are needed to reach a definitive classification.	26021864, 15632069, 30388402, 30315573	https://www.clinicalgenome.org/site/assets/files/3975/gene-disease_validity_standard_operating_procedures_version_7-1.pdf	100005	2020-10-15
GENCC_000105-HGNC_5044-MONDO_0014700-HP_0000006-GENCC_100002	HGNC:5044	HNRNPK	MONDO:0014700	neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-hip dysplasia syndrome due to a point mutation	MONDO:0014700	neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-hip dysplasia syndrome due to a point mutation	GENCC:100002	Strong	HP:0000006	Autosomal dominant	GENCC:000105	Illumina	HGNC:5044	HNRNPK	MONDO:0014700	Au-Kline syndrome	HP:0000006	Autosomal dominant inheritance	GENCC:000105	Illumina	GENCC:100002	Strong	2020-09-25 00:00:00		The HNRNPK gene is located on chromosome 9 at 9q21.32 and encodes the heterogeneous nuclear ribonucleoprotein K protein, which is one of the major pre-mRNA-binding proteins. HNRNPK was first reported in association with Au Kline syndrome in 2015 (26173930: Au et al. 2015).  Evidence supporting this gene-disease relationship includes case-level data and experimental data. At least eight de novo heterozygous variants have been reported in the literature, including fives loss-of-function variants, two missense variants, and one intron variant predicted to result in an inframe insertion, in six publications (26173930: Au et al. 2015; 26954065: Lange et al. 2016; 28771707: Miyake et al. 2017; 28374925: Dentici et al. 2017; 29904177: Au et al. 2018; 32588992: Yamada et al. 2020). The mechanism for disease is loss-of-function. The hnRNP K protein was shown to be expressed in rat hippocampal neuron and colocalized with VGLUT1 (a presynaptic protein) and PSD-95 (a postsynaptic scaffolding protein), and in mouse leukemic monocyte macrophage RAW264.7 cells, a significant increase in GSK3β-hnRNPK interaction was observed (24990929: Folci et al. 2014; 26638989: Fan et al. 2015). In summary, there is strong evidence to support the relationship between HNRNPK and Au Kline syndrome (autosomal dominant).	26173930, 26954065, 28771707, 28374925, 29904177, 32588992, 26638989, 24990929	https://www.clinicalgenome.org/site/assets/files/3975/gene-disease_validity_standard_operating_procedures_version_7-1.pdf	100006	2020-10-15
GENCC_000105-HGNC_16466-MONDO_0007187-HP_0000006-GENCC_100001	HGNC:16466	SUFU	MONDO:0007187	nevoid basal cell carcinoma syndrome	MONDO:0007187	nevoid basal cell carcinoma syndrome	GENCC:100001	Definitive	HP:0000006	Autosomal dominant	GENCC:000105	Illumina	HGNC:16466	SUFU	MONDO:0007187	nevoid basal cell carcinoma syndrome	HP:0000006	Autosomal dominant inheritance	GENCC:000105	Illumina	GENCC:100001	Definitive	2020-09-08 00:00:00		The SUFU gene is located on chromosome 10 at 10q24.32 and encodes the suppressor of fused homolog protein, which is a negative regulator for the hedgehog/smoothened signaling pathway. The SUFU gene was first reported in relation to Gorlin syndrome (known as nevoid basal cell carcinoma syndrome) and atypical Gorlin syndrome, in 2009 (19533801; Pastorino et al. 2009). Evidence supporting this gene-disease relationship includes case-level data and experimental data. From a selection of literature, at least seven variants have been reported in a heterozygous state in eight affected individuals in six publications (19533801: Pastorino et al. 2009; 22829011: Kijima et al. 2012; 25403219: Smith et al. 2014; 29892665: Ogden et al. 2018; 29356994: Huq et al. 2018; 31485359: Askaner et al. 2019). The mechanism for disease is loss of function. Experimental evidence demonstrates that a splice donor variant was unable to interact with GLI transcription factors, resulting in activation of SHH pathway target genes (12068298: Taylor et al. 2002; 16459298: Svard et al. 2006). In a mouse model, in which mice were heterozygous for functional Sufu, a skin phenotype similar to Gorlin syndrome was observed (16459298: Svard et al. 2006). In summary, SUFU is definitively associated with autosomal dominant nevoid basal cell carcinoma syndrome.	19533801, 22829011, 25403219, 29892665, 29356994, 31485359, 12068298, 16459298	https://www.clinicalgenome.org/site/assets/files/3975/gene-disease_validity_standard_operating_procedures_version_7-1.pdf	100007	2020-10-15
GENCC_000105-HGNC_16050-MONDO_0030030-HP_0000006-GENCC_100003	HGNC:16050	MED12L	MONDO:0030030	Nizon-Isidor syndrome	MONDO:0030030	Nizon-Isidor syndrome	GENCC:100003	Moderate	HP:0000006	Autosomal dominant	GENCC:000105	Illumina	HGNC:16050	MED12L	MONDO:0030030	Nizon-Isidor syndrome	HP:0000006	Autosomal dominant inheritance	GENCC:000105	Illumina	GENCC:100003	Moderate	2020-06-16 00:00:00		MED12L was first reported in relation to autosomal dominant Nizon-Isidor syndrome in 2019 (31155615: Nizon et al. 2019). Evidence supporting this gene-disease relationship includes case-level data and experimental data. Variants in this gene have been reported in at least four probands in one publication (31155615: Nizon et al. 2019). The four variants were all predicted loss of function and included a frameshift, a stop gained and two splice variants and at least two occurred de novo. This gene-disease relationship is supported by expression data and protein interaction data; MED12L is a component of the kinase module of the Mediator complex, other subunits of the kinase module have also been implicated in intellectual disability, including MED12, MED13L, MED13 and CDK19 (28778422: Jeronimo et al. 2017). In summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.	31155615, 28778422	https://www.clinicalgenome.org/site/assets/files/3975/gene-disease_validity_standard_operating_procedures_version_7-1.pdf	100008	2020-10-15
